Select Cognition Coverage and Published Editorials
Oral Zervimesine Slows Geographic Atrophy Progression in Phase 2 Dry AMD Trial
Ophthalmology Breaking News
May 14, 2025
Cognition Therapeutics Data Shows Retinal Cell Health Impact
Clinical Trial Vanguard
By Jon Napitupulu
May 12, 2025
Zervimesine Robustly Slows Geographic Atrophy Lesion Growth in Latest Phase 2 MAGNIFY Data
Neurology Live
By Marco Meglio
May 10, 2025
Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial
HCPLive
By Ryan Livingston
May 8, 2025
Caregiver Distress: The Hidden Burden Of Dementia With Lewy Bodies — And Why Measuring It Matters
Clinical Leader
By Anthony Caggiano, MD, Ph.D., and Theresa Devins, DrPH, MS
May 7, 2025
Assessing Investigational CT1812’s Impact on Tau, Amyloid, and Neurodegeneration
Neurology Live
By Marco Meglio
April 3, 2025
Connect with us on Social Media

